Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 10, 2009, Pages 1629-1632

  Schmid, P ^a   Brodmann, D ^b   Odermatt, Y ^a   Fischer, A G ^b   Wuillemin, W A ^c  

^a Division of Hematology and Central Hematology Laboratory   (Switzerland)

^b Division of Nephrology   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Dalteparin; Low molecular weight heparin; Pharmacokinetics; Renal insufficiency; Therapy

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DALTEPARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; LUNG EMBOLISM; MALE; PRIORITY JOURNAL; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DALTEPARIN; FACTOR XA; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INJECTIONS, SUBCUTANEOUS; INPATIENTS; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 70350001803     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03556.x     Document Type: Article

References (12)

1. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:141S-59S.
2. Sohal AS, Gangji AS, Crowther MA, Treleaven D. Uremic bleeding: Pathophysiology and clinical risk factors. Thromb Res 2006, 118:417-22.
3. Schmid P, Fischer AG, Wuillemin WA. Low-molecular-weight heparin in patients with renal insufficiency. Swiss Med Wkly 2009, 139:438-52.
4. Shprecher AR, Cheng-Lai A, Madsen EM, Cohen HW, Sinnett MJ, Wong ST, Billett HH. Peak antifactor Xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. Pharmacotherapy 2005, 25:817-22.
5. Schmid P, Brodmann D, Fischer AG, Wuillemin WA. Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. J Thromb Haemost 2009, 7:552-8.
6. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003, 139:137-47.
7. Heizmann M, Baerlocher GM, Steinmann F, Horber FF, Wuillemin WA. Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis. Thromb Res 2002, 106:179-81.
8. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:454S-545S.
9. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:257S-98S.
10. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006, 144:673-84.
11. Monreal M, Falgá C, Valle R, Barba R, Bosco J, Beato JL, Maestre A. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE registry. Am J Med 2006, 119:1073-9.
12. Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004, 110:392-8.